Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems - Wikidata - wikimedia - TriplyDB

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

http://www.wikidata.org/entity/Q34998994

about

Cancer stem cell division: when the rules of asymmetry are broken Targeting TBP-Associated Factors in Ovarian Cancer Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer Recent concepts of ovarian carcinogenesis: type I and type II Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival.DNA methylation changes in epithelial ovarian cancer histotypes.Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells Type-specific cell line models for type-specific ovarian cancer research Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review.MALDI Imaging Mass Spectrometry (MALDI-IMS)-application of spatial proteomics for ovarian cancer classification and diagnosis.NuMA overexpression in epithelial ovarian cancer.Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas Poor survival with wild-type TP53 ovarian cancer?Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials.KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.BRCA-associated ovarian cancer: from molecular genetics to risk management Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.Fallopian tube origin of supposed ovarian high-grade serous carcinomas.miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma An immunocompetent, orthotopic mouse model of epithelial ovarian cancer utilizing tissue engineered tumor cell sheets

P2860

Q26851679-6F4B0EB7-3D16-4F2D-AF4E-2BB14B23FE39 Q26866045-DE04AB21-F832-4DA3-A147-4CE4C1C30530 Q27009306-093EA8E0-A69B-4F8A-9C47-2966EC4CE85E Q27009487-3824F4BA-883C-4A6F-BD80-58EF62785F2B Q27320720-F7EB633B-1AE2-4B92-95FA-556D8EBAD949 Q27690722-FE805353-828E-4FEF-8198-40DC1CEE37BB Q28070226-247AEB0A-2B2D-460C-A400-71AE05032C17 Q28484496-8883540D-8864-4CAC-A835-A52E57D67A82 Q28536689-60FD2E92-565A-4DA8-BA28-19AE2DB9D523 Q28550381-4F99139A-8732-4222-838B-2E63A9DCA786 Q28741689-FA03F54A-E195-4397-85BA-275F84435852 Q30248280-7EB73164-91C9-480A-A20B-A4D452D48CB7 Q30476935-F64D1029-6294-4298-B995-8BD722184878 Q31068680-4ED7F2E5-9EC0-47BA-A380-6F4222B05AF5 Q33638206-077ED55F-1B84-43ED-9FCD-243006BBE3D5 Q33638726-5734A85C-EBA5-422D-AAC3-F1FFBF36EB38 Q33655094-78D3D27B-649F-48AB-ABDD-AF692FB0474B Q33693203-74664A3B-1EBD-4DFF-8826-395996BB486E Q33735170-5BA3F77D-2EBD-47CF-9B01-3EF92CFE19AF Q33758727-558C93C0-7EE7-4774-8810-4D81ABC66DD1 Q33761535-FFE5CBC7-B3E4-4366-A411-7FAE02878BF2 Q33850475-EEA2F17B-FEEA-43B8-B707-674045F4F166 Q33893010-58A1CF87-9A6E-472D-A2A2-6F3051196C9A Q33971294-31B936DC-0AE9-4508-9D4F-082E3ACD47B7 Q34022694-BA21B636-0DB4-46D1-BC63-3CB1D5B574D1 Q34032766-B972092A-654C-418C-A69A-2AF2B8E34E17 Q34097804-CE87EDC3-89FE-46EC-899A-A76BD0B9F667 Q34103978-CFCBB8C6-A71F-4F90-9F77-D7458370716C Q34121226-2EB0766E-9F6B-4C9C-8AF1-593BFEF25FA7 Q34162272-2C550328-38CC-48A6-8E67-9331F48A45E0 Q34189765-A9FEE35C-DB0D-4316-88DC-D934D306E6F7 Q34338047-FD98DB8F-BC80-423E-9947-509DEC57F45E Q34371477-39ED4757-0EEC-4EB9-9025-30FF883B4107 Q34381630-B4F9FA9E-747D-4325-94AC-D72478CBB36A Q34431079-CE6382E8-4E2A-4ACB-8C02-5138F5CEF429 Q34528553-5D426C3E-6886-461F-9151-24F1518F5C62 Q34565756-C11030F7-DED3-42B7-9BE6-FBEE89F0F875 Q34604042-8A423E96-8891-4D9B-9AC3-471FD0E6A85A Q34786575-751DDC53-B5FF-404E-B107-7395835751C8 Q34919480-69983E1D-2EFE-42A5-A766-2FBBDD230C4C

P2860

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

http://www.wikidata.org/entity/Q34998994

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@ast

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@en

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@nl

type

label

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@ast

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@en

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@nl

prefLabel

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@ast

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@en

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@nl

P1433

Q34998994-F64A8685-C2F6-470F-9EE1-AE3F4AF88ADC

P1476

Q34998994-16361FA4-6534-47C9-A1A6-643CE5F83A9B

P2093

Q34998994-B8372028-FBCF-44D4-9D39-656969FD9D70

Q34998994-BB6BEB3A-CB51-4A4E-857E-11A9B2FB3E4D

Q34998994-F49E5181-8ADD-4A94-82C3-98A759F795EA

P2860

Q34998994-00DBB508-EE16-494A-8897-65850F4AC02B

Q34998994-03D2EB5D-AA60-4F18-BBFB-9515898633F8

Q34998994-0653B38E-6A9B-46CD-AECE-E2CD095BD48F

Q34998994-077CA0D1-E5CA-4C5E-A3CE-1CB3F967B1E2

Q34998994-15AD425A-FBCF-420A-9ACC-9DA5B5B3C2C7

Q34998994-161416B0-00BC-42E4-ACA0-6891F8801EBF

Q34998994-1D990882-6120-4A93-81A3-ACEFF833955F

Q34998994-1F8BCFF4-5162-4CBC-A363-359E383B50C1

Q34998994-24103E26-CBDE-45FB-8867-2346C81FAA9E

Q34998994-2BC4FF24-BB84-464C-9A58-30B87993E265

P304

Q34998994-DD0C1116-4655-472A-9727-CE7836993CA4

P31

Q34998994-B3564D24-C821-41D6-B6B0-AEAD58223FD8

P356

Q34998994-0A71EB2B-1FEF-4DCD-BCC8-07A0C9B936D9

P433

Q34998994-7818CE24-F25C-4EC9-A379-9DC206251C42

P478

Q34998994-41D7CD6B-61D2-4B1B-882C-9E1C17B7D28E

P577

Q34998994-B1EF4DF5-5803-4AFF-BDD5-470DBE8CA037

P698

Q34998994-2ED30120-535D-4538-BB78-3E2AE5333AB2

P921

Q34998994-a6a97c21-9f57-4714-90bd-ebc74fb73e3c

P932

Q34998994-111C5904-2F4D-4FE7-A2E8-EFDB94B50189

P356

PAP.0B013E3181B4FFFA

P1433

Advances in Anatomic Pathology

P1476

Ovarian low-grade and high-gra ...... tures, and diagnostic problems

@en

P2093

Ie-Ming Shih

http://www.w3.org/2001/XMLSchema#string

Robert J Kurman

http://www.w3.org/2001/XMLSchema#string

Russell Vang

http://www.w3.org/2001/XMLSchema#string

P2860

A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival

Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma

Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy

Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period

Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.

K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.

Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.

Histopathologic grading of ovarian carcinoma: a review and proposal.

P304

267-282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAP.0B013E3181B4FFFA

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19700937

http://www.w3.org/2001/XMLSchema#string

P921

P932

2745605

http://www.w3.org/2001/XMLSchema#string